Qiagen NV (QGEN) stock: key figures, P/E, revenue and dividend
Health Care · Netherlands · ISIN NL0015002SN0
Qiagen NV financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.09 bn USD |
| Gross profit | 1.30 bn USD |
| Operating income | 465.85 m USD |
| EBIT | 520.00 m USD |
| Net income | 424.88 m USD |
| Diluted EPS – continuing operations | 1.94 USD |
Full history since 1991, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
More stocks
- China Shipbuilding Industry Group Power Co Ltd (600482.SS)
- Antero Midstream Corp (AM)
- HECLA MINING CO/DE/ (HL)
- M&G PLC (MNG.L)
- DARLING INGREDIENTS INC. (DAR)
- Han'S Laser Tech A (002008.SZ)
- Kakao Corp (035720.KS)
- LITTELFUSE INC /DE (LFUS)
- Forgent Power Solutions, Inc. (FPS)
- POPULAR, INC. (BPOP)
- Sofina SA (SOF.BR)
- Lululemon Athletica (LULU)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.